<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704453</url>
  </required_header>
  <id_info>
    <org_study_id>20 VADS 04</org_study_id>
    <nct_id>NCT04704453</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.</brief_title>
  <acronym>TEC-ORL</acronym>
  <official_title>Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the analgesic activity of capsaicin patch 8% applications at 3&#xD;
      months interval each on the cervico-facial area versus a reference neuropathic treatment with&#xD;
      amitriptyline in patients with head and neck cancer in remission and with sequelae&#xD;
      neuropathic pain.&#xD;
&#xD;
      In this phase II trial, patients will be assigned in one of the two treatment arms:&#xD;
&#xD;
        -  Arm A (Experimental arm): Capsaïcin patch (Qutenza®)&#xD;
&#xD;
        -  Arm B (standard arm): Amitriptyline (Laroxyl®)&#xD;
&#xD;
           130 patients will be included and will be followed during 9 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of patients with a decrease in average pain over the last 24 hours by 2 points at 9 months compared to inclusion.</measure>
    <time_frame>9 months for each patient</time_frame>
    <description>Pain will be assessed using a numerical scale from 0 to 10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain according to the Neuropathic Pain Symptom Inventory (NPSI) questionnaire.</measure>
    <time_frame>9 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of the drugs evaluated using the NCI-CTC AE V5.</measure>
    <time_frame>9 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluated according to the Quality of Life Questionnaire-Core 30 (QLQ-C30).</measure>
    <time_frame>9 months for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental arm (A): capsaicin patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard arm (B): amitriptyline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaïcin patch (Qutenza®)</intervention_name>
    <description>Treatment by application of capsaicin 8% (Qutenza®) patches 3 months apart (Month 1, Month 4 and Month 7).</description>
    <arm_group_label>Experimental arm (A): capsaicin patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amitriptyline (Laroxyl®)</intervention_name>
    <description>Treatment by amitriptyline (oral solution 40mg/ml), for 9 months at the recommended dose of 25 mg to 75 mg daily.</description>
    <arm_group_label>Standard arm (B): amitriptyline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. ORL cancer in remission: absence of clinical or radiological signs of progression at&#xD;
             least 3 months after specific treatments.&#xD;
&#xD;
          3. Pain of the cervico-facial sphere persisting for more than 3 months after surgical&#xD;
             and/or radiotherapy treatment.&#xD;
&#xD;
          4. Peripheral neuropathic character of pain objectified to a score ≥ 4/10 on the DN4&#xD;
             questionnaire.&#xD;
&#xD;
          5. Pain whose average intensity over the last 24 hours is assessed on the numerical scale&#xD;
             as ≥ 2/10.&#xD;
&#xD;
          6. Postmenopausal patient or patient who agrees to use effective contraception for the&#xD;
             duration of treatment and for a minimum of 15 days after the end of the treatment&#xD;
             period. Non-menopausal patients must have a negative pregnancy test prior to inclusion&#xD;
             in the study.&#xD;
&#xD;
          7. Patient affiliated to a Social Health Insurance in France.&#xD;
&#xD;
          8. Patient who signed informed consent prior to inclusion in the study and prior to any&#xD;
             specific study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ORL cancer in progression.&#xD;
&#xD;
          2. Other concomitant neoplasia (progressive or not).&#xD;
&#xD;
          3. Central etiology of pain.&#xD;
&#xD;
          4. Pain whose average intensity over the last 24 hours is assessed on the numerical scale&#xD;
             as &lt; 2/10.&#xD;
&#xD;
          5. Allergy to any of the components of the capsaicin patch.&#xD;
&#xD;
          6. Capsaicin patch not applicable to the area to be treated despite the precautions&#xD;
             described in the protocol because of its proximity to mucous membranes or eyelids.&#xD;
&#xD;
          7. Contraindication to amitriptyline treatment.&#xD;
&#xD;
          8. Patient with an unhealed skin lesion on the area to be treated.&#xD;
&#xD;
          9. Previous treatment with capsaicin or amitriptyline.&#xD;
&#xD;
         10. Topical treatment of the painful area used for more than 21 days before inclusion.&#xD;
&#xD;
         11. Ongoing opioid treatment &gt; 80mg/day oral morphine equivalent.&#xD;
&#xD;
         12. Uncontrolled high blood pressure or cardiovascular history (infarction, stroke,&#xD;
             pulmonary embolism) less than 3 months ago.&#xD;
&#xD;
         13. Patient included in another interventional therapeutic trial.&#xD;
&#xD;
         14. Pregnant or breastfeeding patient.&#xD;
&#xD;
         15. Any psychological, family, geographical or sociological condition that prevents&#xD;
             compliance with the medical follow-up and/or procedures of the study protocol.&#xD;
&#xD;
         16. Patient who has forfeited his/her freedom by administrative or legal award or who is&#xD;
             under legal protection (curatorship and guardianship, protection of justice).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine BODEN</last_name>
    <phone>05 31 15 57 91</phone>
    <email>boden.antoine@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>INSTITUT DE CANCEROLOGIE DE L'OUEST (ICO) Site Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry DELORME</last_name>
      <phone>02 41 35 27 00</phone>
      <email>thierry.delorme@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alix DOUSSET</last_name>
      <phone>04 91 80 67 63</phone>
      <email>adousset@hopital-saint-joseph.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine BODEN, MD</last_name>
      <phone>05 31 15 57 91</phone>
      <email>boden.antoine@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropathic Pain</keyword>
  <keyword>Capsaicin patch</keyword>
  <keyword>Amitriptyline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

